Other

The University of British Columbia

Zymeworks Inc.

Cdrd Ventures Inc.

Jan Peter Bergqvist

John Stephen Babcook

Christopher John Bond

Bradley John Hedberg

Michael R Hughes

Calvin D Roskelley

Diana Canals Hernaez

Klas Ola Blixt

Ismael Samudio

Katherine Grace MacDonald

Anna Von Rossum

Pamela Megan Dean

James R Rich

Stuart Daniel Barnscher

Kelly Marshall McNagny

Caroline Lamarche

Megan Levings

Kelley Marshall Mcnagny

Nicholas Dawson

Paul Orban

The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.

Anti-podocalyxin antibodies and methods of using the same

Provided are humanized anti-HLA-A2 antibodies. In certain aspects, the humanized anti-HLA-A2 antibodies are capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), where the CAR is capable of being expressed in a human cell such that the CAR specifically binds to HLA-A2. Also provided are CARs that include the humanized anti-HLA-A2 antibodies. Modified cells including the antibodies and CARs, as well as methods of using such modified cells are also provided.

Anti-hla-A2 antibodies and methods of using the same

The present disclosure provides light chain polypeptides that include a C-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the C-terminal extension includes one or more cysteine residues. Conjugates that include an antibody of the present disclosure conjugated to an agent via the cysteine residue of the C-terminal amino acid extension are also provided. The present disclosure further provides nucleic acids encoding an antibody light chain polypeptide that includes a C-terminal amino acid extension including a cysteine residue. Pharmaceutical compositions including the antibodies or conjugates of the present disclosure are also provided, as are methods of making and use of the modified anti-bodies and conjugates of the present disclosure.

Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof

Growing community of inventors

Vancouver, Canada

Jan Peter Bergqvist